Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016
Total Revenue of $4.1 Million Increased 24%—Led by 64% Increase in Product Revenue—Driven by Growth in U.S. Dermatology Sales
Conference Call at 4:30 pm ET Today
PETALUMA, Calif. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), warrants (Nasdaq:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the second quarter of fiscal year 2016 ended September 30, 2015.
Total revenue was $4.1 million for the second quarter, an increase of 24%, when compared to $3.3 million for the same period in 2014. Product revenues were up 64% from the same period last year, led by increases in the United States dermatology market and the rest of world.
“Oculus’ second quarter benefited from the strategic decision we made in late 2014 to enter the U.S. dermatology market directly. At that time, we deployed a direct U.S. sales force followed by the launch of six prescription dermatology products. This expanded our presence in the dermatology market, with its strong pricing reimbursement and rapid sales ramps, has resulted in significant sales growth in the U.S. over the last nine months," said Oculus CEO Jim Schutz. “We believe the growth in the dermatology sales will continue as we launch new products, expand our existing product lines and hire additional sales people.”
Results for the Three Months Ended September 30, 2015
Product revenue in the United States was $1.2 million for the three months ended September 30, 2015, as compared to $356,000 in the quarter ended September 30, 2014. Product revenues increased $830,000, or 233%, from the same period last year primarily due to higher dermatology sales. The growth in dermatology was the result of sales increases in four existing products for the treatment of atopic dermatitis, scars and surgical procedures, launched prior to this quarter and two new products, including an oral drug, which were shipped to wholesalers during the second quarter.
Product revenue in Europe and the rest of the world for the quarter ended September 30, 2015, increased by $399,000, or 72%, to $952,000 as compared to the same period in the prior year, with increases in Asia and Middle East, which were slightly offset by a modest sales decrease in Europe. The decrease in Europe is the result of the impact of a 19% decline in the euro, mostly offset by a 15% increase in local currency sales growth for the quarter. In addition, there were initial sales to new sales partners in India and New Zealand during the second quarter.
Product revenue in Latin America for the three months ended September 30, 2015, was $1.3 million, an increase of $99,000, or 8%, when compared to the same period in the prior year, impacted by a 26% decline in the peso. On a local currency basis, product revenue growth was 36% compared to the same period last year. This growth in sales is primarily due to a much larger sales force and distribution network of Oculus’ new partner, Laboratorios Sanfer, which acquired the company’s former partner in January 2015.
For the three months ended September 30, 2015 and 2014, product licensing fees and royalty revenues were $339,000 and $997,000, respectively. The decrease is primarily related to the termination of Oculus’ agreement with its former animal healthcare partner.
Oculus reported gross profit related to its products of $2.0 million, or 54% of product related revenues, during the three months ended September 30, 2015, compared to a gross profit of $1.7 million, or 55% of total product related revenues, for the same period in the prior year. Product licensing fees and royalty revenues are included in the calculation of gross profit for the quarters ended September 30, 2015 and 2014.
Total operating expenses of $3.9 million for the three months ended September 30, 2015, increased by $672,000, or 21%, as compared to the same period in the prior year. Operating expenses minus non-cash expenses during the second quarter of fiscal year 2015 were $3.5 million, up $641,000, as compared to the same period in the prior year. The increase in operating expenses, minus non-cash expenses, was due to higher sales and marketing expenses in the United States related to the costs of a direct sales force in dermatology.
Net loss for the three months ended September 30, 2015, was $1.8 million, compared to net loss of $718,000 for the same period in the prior year. The higher net loss was primarily due to an $841,000 gain resulting from a change in the fair value of derivative liabilities in the prior year period which did not reoccur this quarter and, to a lesser extent, an increase in sales and marketing costs in the United States.
As of September 30, 2015, Oculus had unrestricted cash and cash equivalents of $8.0 million, as compared with $6.1 million as of March 31, 2015. The company has no debt outstanding.
Results for the Six Months Ended September 30, 2015
Total revenues of $7.7 million increased by $1.1 million, or 16%, for the six months ended September 30, 2015, as compared to $6.7 million for the six months ended September 30, 2014. Product revenue of $6.3 million increased $2.1 million, or 51%, with strong growth in all major segments, led by product revenue growth in the United States of $1.3 million, an increase of 177%. Latin America’s revenue was up 25%, despite a 21% decline in the peso and rest of world’s revenue was up 24% with strong growth in Asia.
Oculus reported gross profit related to sales of its products of $3.9 million, or 55% of product revenues, for the six months ended September 30, 2015, compared to a gross profit of $3.6 million, or 57% of product revenues, for the same period in the prior year.
Total operating expenses less non-cash expenses increased $1.4 million, or 24%, for the six months compared to the same period in the prior year, primarily due to higher sales costs for the direct sales force for dermatology. Operating loss less non-cash expenses (EBITDAS) for the six months ended September 30, 2015, was $3.0 million, compared to $2.0 million for the same period last year. The net loss for the six months ended September 30, 2014 includes a non-cash gain of $2.3 million due to a reduction in Oculus’ derivative liability relating to certain warrants, resulting in a non-cash change in net loss from the six months ended September 30, 2015 compared to the same period last year.
Conference Call
Oculus’ management will hold a conference call today to discuss second quarter fiscal year 2016 results and answer questions, beginning at 4:30 p.m. ET. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers.
Those interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 57505646. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “continue,” “expand,” “hire,” and “launch,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s common stock and warrants may be delisted from NASDAQ, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Oculus and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
| OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| September 30, |
March 31, |
|||||||
| 2015 | 2015 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 7,974 | $ | 6,136 | ||||
| Accounts receivable, net | 2,572 | 1,517 | ||||||
| Inventories, net | 1,670 | 1,402 | ||||||
| Prepaid expenses and other current assets | 461 | 592 | ||||||
| Total current assets | 12,677 | 9,647 | ||||||
| Property and equipment, net | 835 | 795 | ||||||
| Long-term investment | – | 4,538 | ||||||
| Other assets | 72 | 68 | ||||||
| Total assets | $ | 13,584 | $ | 15,048 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,161 | $ | 932 | ||||
| Accrued expenses and other current liabilities | 1,016 | 782 | ||||||
| Deferred revenue | 391 | 769 | ||||||
| Current portion of long-term debt | – | 87 | ||||||
| Derivative liabilities | 5 | 11 | ||||||
| Total current liabilities | 2,573 | 2,581 | ||||||
| Deferred revenue, less current portion | 263 | 413 | ||||||
| Total liabilities | 2,836 | 2,994 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity | ||||||||
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized, none issued and outstanding at September 30, 2015 and March 31, 2015, respectively |
– | – | ||||||
| Common stock, $0.0001 par value; 30,000,000 shares authorized, 16,415,765 and 15,045,080 shares issued and outstanding at September 30, 2015 and March 31, 2015, respectively |
2 | 2 | ||||||
| Additional paid-in capital | 160,893 | 157,772 | ||||||
| Accumulated deficit | (146,316 | ) | (142,213 | ) | ||||
| Accumulated other comprehensive loss | (3,831 | ) | (3,507 | ) | ||||
| Total stockholders’ equity | 10,748 | 12,054 | ||||||
| Total liabilities and stockholders’ equity | $ | 13,584 | $ | 15,048 | ||||
| OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES | ||||||||||||||||
| Condensed Consolidated Statements of Comprehensive Loss | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, |
Six Months Ended September 30, |
|||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Revenues | ||||||||||||||||
| Product | $ | 3,404 | $ | 2,076 | $ | 6,320 | $ | 4,197 | ||||||||
| Product licensing fees and royalties | 339 | 997 | 786 | 2,046 | ||||||||||||
| Service | 311 | 191 | 628 | 413 | ||||||||||||
| Total revenues | 4,054 | 3,264 | 7,734 | 6,656 | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Product | 1,717 | 1,368 | 3,233 | 2,690 | ||||||||||||
| Service | 247 | 164 | 538 | 328 | ||||||||||||
| Total cost of revenues | 1,964 | 1,532 | 3,771 | 3,018 | ||||||||||||
| Gross profit | 2,090 | 1,732 | 3,963 | 3,638 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 412 | 353 | 879 | 792 | ||||||||||||
| Selling, general and administrative | 3,536 | 2,923 | 7,253 | 5,904 | ||||||||||||
| Total operating expenses | 3,948 | 3,276 | 8,132 | 6,696 | ||||||||||||
| Loss from operations | (1,858 | ) | (1,544 | ) | (4,169 | ) | (3,058 | ) | ||||||||
| Interest expense | (1 | ) | (1 | ) | (1 | ) | (4 | ) | ||||||||
| Interest income | 1 | – | 1 | – | ||||||||||||
| Gain due to change in fair value of derivative liabilities | 65 | 841 | 6 | 2,319 | ||||||||||||
| Other income (expense), net | 30 | (14 | ) | 60 | (45 | ) | ||||||||||
| Net loss | $ | (1,763 | ) | $ | (718 | ) | $ | (4,103 | ) | $ | (788 | ) | ||||
| Net loss per common share: basic and diluted | $ | (0.11 | ) | $ | (0.08 | ) | $ | (0.26 | ) | $ | (0.09 | ) | ||||
| Weighted-average number of shares used in per common share calculations: | ||||||||||||||||
| Basic and diluted | 16,257 | 8,503 | 15,721 | 8,425 | ||||||||||||
| Other comprehensive loss | ||||||||||||||||
| Net loss | $ | (1,763 | ) | $ | (718 | ) | $ | (4,103 | ) | $ | (788 | ) | ||||
| Foreign currency translation adjustments | (253 | ) | (110 | ) | (324 | ) | (102 | ) | ||||||||
| Comprehensive loss | $ | (2,016 | ) | $ | (828 | ) | $ | (4,427 | ) | $ | (890 | ) | ||||
| OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES | ||||||||||||||||
| Reconciliation of GAAP Measures to Non-GAAP Measures | ||||||||||||||||
| (In thousands) and (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, |
Six Months Ended September 30, |
|||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| (1) Loss from operations minus non-cash expenses (EBITDAS): | ||||||||||||||||
| GAAP loss from operations as reported | $ | (1,858 | ) | $ | (1,544 | ) | $ | (4,169 | ) | $ | (3,058 | ) | ||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | 492 | 456 | 1,011 | 907 | ||||||||||||
| Depreciation and amortization | 60 | 37 | 122 | 101 | ||||||||||||
| Non-GAAP loss from operations minus non-cash expenses (EBITDAS) | $ | (1,306 | ) | $ | (1,051 | ) | $ | (3,036 | ) | $ | (2,050 | ) | ||||
| (2) Net loss minus non-cash expenses: | ||||||||||||||||
| GAAP net loss as reported | $ | (1,763 | ) | $ | (718 | ) | $ | (4,103 | ) | $ | (788 | ) | ||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | 492 | 456 | 1,011 | 907 | ||||||||||||
| Depreciation and amortization | 60 | 37 | 122 | 101 | ||||||||||||
| Gain due to change in fair value of derivative instruments | (65 | ) | (841 | ) | (6 | ) | (2,319 | ) | ||||||||
| Non-GAAP net loss minus non-cash expenses | $ | (1,276 | ) | $ | (1,066 | ) | $ | (2,976 | ) | $ | (2,099 | ) | ||||
| (3) Operating expenses minus non-cash expenses | ||||||||||||||||
| GAAP operating expenses as reported | $ | 3,948 | $ | 3,276 | $ | 8,132 | $ | 6,696 | ||||||||
| Non-cash adjustments: | ||||||||||||||||
| Stock-based compensation | (430 | ) | (397 | ) | (894 | ) | (784 | ) | ||||||||
| Depreciation and amortization | (11 | ) | (13 | ) | (23 | ) | (25 | ) | ||||||||
| Non-GAAP operating expenses minus non-cash expenses | $ | 3,507 | $ | 2,866 | $ | 7,215 | $ | 5,887 | ||||||||
| (1) Loss from operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. | ||||||||||||||||
| (2) Net loss minus non-cash expenses is a non-GAAP financial measure. The Company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, a change in fair value of common stock, a change in the fair value of derivative instruments, loss on impairment of investment, and non-cash interest expense. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. | ||||||||||||||||
| (3) Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. | ||||||||||||||||
OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES
Product Related Revenue Schedules
(In thousands) and (Unaudited)
The following table shows our product revenues by geographic region:
| Three Months Ended September 30, | ||||||||||||||||||
| Geographic Region | 2015 | 2014 | $ Change |
% Change |
||||||||||||||
| United States | $ | 1,186 | $ | 356 | $ | 830 | 233 | % | ||||||||||
| Latin America | 1,266 | 1,167 | 99 | 8 | % | |||||||||||||
| Europe and Rest of the World | 952 | 553 | 399 | 72 | % | |||||||||||||
| 3,404 | 2,076 | 1,328 | 64 | % | ||||||||||||||
| Product license fees and royalties | 339 | 997 | (658 | ) | (66 | % | ) | |||||||||||
| Total | $ | 3,743 | $ | 3,073 | $ | 670 | 22 | % | ||||||||||
The following table shows our product license fees and royalties revenue by partner:
| Three Months Ended September 30, | ||||||||||||||||||
| Partner | 2015 | 2014 | $ Change |
% Change |
||||||||||||||
| Exeltis (formerly Quinnova) | $ | 103 | $ | 161 | $ | (58 | ) | (36 | ) | % | ||||||||
| Innovacyn | 9 | 459 | (450 | ) | (98 | ) | % | |||||||||||
| Laboratorios Sanfer (formerly More Pharma) | 227 | 377 | (150 | ) | (40 | ) | % | |||||||||||
| Total product license fees and royalties | $ | 339 | $ | 997 | $ | (658 | ) | (66 | ) | % | ||||||||
The following table shows our product revenues by geographic region:
| Six Months Ended September 30, | ||||||||||||||||||
| Geographic Region | 2015 | 2014 | $ Change |
% Change |
||||||||||||||
| United States | $ | 1,973 | $ | 711 | $ | 1,262 | 177 | % | ||||||||||
| Latin America | 2,824 | 2,260 | 564 | 25 | % | |||||||||||||
| Europe and Rest of the World | 1,523 | 1,226 | 297 | 24 | % | |||||||||||||
| 6,320 | 4,197 | 2,123 | 51 | % | ||||||||||||||
| Product license fees and royalties | 786 | 2,046 | (1,260 | ) | (62 | % | ) | |||||||||||
| Total | $ | 7,106 | $ | 6,243 | $ | 863 | 14 | % | ||||||||||
The following table shows our product license fees and royalties revenue by partner:
| Six Months Ended September 30, | ||||||||||||||||||
| Partner | 2015 | 2014 | $ Change | % Change | ||||||||||||||
| Exeltis (formerly Quinnova) | $ | 157 | $ | 307 | $ | (150 | ) | (49 | ) | % | ||||||||
| Innovacyn | 29 | 987 | (958 | ) | (97 | ) | % | |||||||||||
| Laboratorios Sanfer (formerly More Pharma) | 600 | 752 | (152 | ) | (20 | ) | % | |||||||||||
| Total product license fees and royalties | $ | 786 | $ | 2,046 | $ | (1,260 | ) | (62 | ) | % | ||||||||
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 dmcfadden@oculusis.com
Released November 5, 2015